Study on Effective Mydriasis in Premature Infants

Sponsor
Georgetown University (Other)
Overall Status
Completed
CT.gov ID
NCT01054027
Collaborator
(none)
15
1
4
12
1.2

Study Details

Study Description

Brief Summary

The purpose of this study is to compare the dilating effect of 0, 1, 2 or 3 drops of mydriatic (pupil dilating) in premature infants undergoing routine retinal (eye) screening exams for Retinopathy of Prematurity (ROP).

Condition or Disease Intervention/Treatment Phase
  • Drug: 1% phenylephrine and 0.2% cyclopentolate
N/A

Detailed Description

Premature infants need to have eye exams starting at about 4 weeks of age and continuing until their retinas (membrane at the back of the eye which collects and transfers light) is fully grown. These exams are done to see if they have developed ROP, a disease which can lead to blindness if not treated.

The ophthalmologist (eye doctor) looks through the enlarged pupil (opening at the front of the eye) to see the retina. The drug that is used to dilate the pupil, Cyclomydril, has been shown to have side effects in premature infants. No literature has shown what the optimal dose is for premature babies. Nursery policy is to give 3 drops of Cyclomydril in each eye, at 5 minute intervals, 45-60 minutes before a scheduled eye exam. We sought to reduce the dose without delaying the exam for an under-sized pupil.

In the study, each infant is randomized at the time of the exam to receive either 0, 1 or 2 drops of Cyclomydril in the left eye and 3 drops in the right eye to serve as their own control. The zero-drop group was created to test the contralateral (opposite eye) effect of 3 drops in the right eye. Pupil dilation size is measured using the Colvard pupillometer by a Pediatric Ophthalmologist examiner (G.V.V.) who was not masked to study group assignment.

Measures of pupil size are done at baseline (before any drops given), 45, 90 and 120 minutes after the first drop was given. ROP screening exam is done at the first opportunity to visualize the posterior and peripheral retina.

Additional drops are given at 120 minutes if the observer is unable to complete the exam prior to that point.

Study Design

Study Type:
Interventional
Actual Enrollment :
15 participants
Allocation:
Randomized
Intervention Model:
Factorial Assignment
Masking:
None (Open Label)
Primary Purpose:
Screening
Official Title:
A Randomized Controlled Trial to Determine the Lowest Effective Dose for Adequate Mydriasis in Premature Infants
Study Start Date :
Mar 1, 2007
Actual Primary Completion Date :
Nov 1, 2007
Actual Study Completion Date :
Mar 1, 2008

Arms and Interventions

Arm Intervention/Treatment
Experimental: 0 Drop

Left eye dose

Drug: 1% phenylephrine and 0.2% cyclopentolate
given as drops, prior to eye exam
Other Names:
  • Cyclomydril
  • Experimental: 1 Drop

    Left eye dose

    Drug: 1% phenylephrine and 0.2% cyclopentolate
    given as drops, prior to eye exam
    Other Names:
  • Cyclomydril
  • Experimental: 2 drop

    Left eye dose

    Drug: 1% phenylephrine and 0.2% cyclopentolate
    given as drops, prior to eye exam
    Other Names:
  • Cyclomydril
  • Active Comparator: 3 drops

    Right eye dose for all groups

    Drug: 1% phenylephrine and 0.2% cyclopentolate
    given as drops, prior to eye exam
    Other Names:
  • Cyclomydril
  • Outcome Measures

    Primary Outcome Measures

    1. dilation of the pupil in millimeters [at baseline (no drops yet instilled), 45, 90 and 120 minutes after drops instilled]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Premature infants undergoing clinically indicated retinal exams
    Exclusion Criteria:
    • Ocular congenital anomalies

    • Pre-threshold ROP

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Georgetown University Hospital Washington District of Columbia United States 20007

    Sponsors and Collaborators

    • Georgetown University

    Investigators

    • Principal Investigator: Monisha Bahri, MD, Georgetown University Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT01054027
    Other Study ID Numbers:
    • 2007-109
    First Posted:
    Jan 22, 2010
    Last Update Posted:
    Jan 22, 2010
    Last Verified:
    Jan 1, 2010

    Study Results

    No Results Posted as of Jan 22, 2010